PT  - JOURNAL ARTICLE
AU  - Mostkowska, Agata
AU  - Rousseau, Guy
AU  - Raynal, Noël J-M
TI  - Repurposing of rituximab biosimilars to treat B cell mediated autoimmune diseases
AID  - 10.1101/2023.09.22.23295633
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.09.22.23295633
4099  - http://medrxiv.org/content/early/2023/09/25/2023.09.22.23295633.short
4100  - http://medrxiv.org/content/early/2023/09/25/2023.09.22.23295633.full
AB  - Rituximab, the first monoclonal antibody approved for the treatment of lymphoma, eventually became one of the most popular and versatile drugs ever in terms of clinical application and revenue. Since its patent expiration, and consequently, the loss of exclusivity of the original biologic, its repurposing as an off-label drug has increased dramatically, propelled by the development and commercialization of its many biosimilars. Currently, rituximab is prescribed worldwide to treat a vast range of autoimmune diseases mediated by B cells. Here, we present a comprehensive overview of rituximab repurposing in 116 autoimmune diseases across 17 medical specialties, sourced from over 1,530 publications. Our work highlights the extent of its off-label use and clinical benefits, underlining the success of rituximab repurposing for both common and orphan immune-related diseases. We discuss the scientific mechanism associated with its clinical efficacy and provide additional indications for which rituximab could be investigated. Our study presents rituximab as a flagship example of drug repurposing owing to its central role in targeting CD20+ B cells in over 100 autoimmune diseases.Competing Interest StatementThe authors have declared no competing interest.Funding Statement Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present work are contained in the manuscript